Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective
C De Block, C Bailey, C Wysham… - Diabetes, Obesity …, 2023 - Wiley Online Library
Tirzepatide is a novel glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …
[HTML][HTML] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
T Coskun, KW Sloop, C Loghin, J Alsina-Fernandez… - Molecular …, 2018 - Elsevier
Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …
determine whether the metabolic action of GIP adds to the established clinical benefits of …
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide
1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate …
1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate …
Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease
DA Sandoval, DA D'Alessio - Physiological reviews, 2015 - journals.physiology.org
The preproglucagon gene (Gcg) is expressed by specific enteroendocrine cells (L-cells) of
the intestinal mucosa, pancreatic islet α-cells, and a discrete set of neurons within the …
the intestinal mucosa, pancreatic islet α-cells, and a discrete set of neurons within the …
[HTML][HTML] GLP-1 and GIP receptor signaling in beta cells–a review of receptor interactions and co-stimulation
A Mayendraraj, MM Rosenkilde, LS Gasbjerg - Peptides, 2022 - Elsevier
Glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic
polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are …
polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are …
GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
JJ Holst, MM Rosenkilde - The Journal of Clinical Endocrinology …, 2020 - academic.oup.com
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed
to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) …
to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) …
The role of incretins on insulin function and glucose homeostasis
The incretin effect—the amplification of insulin secretion after oral vs intravenous
administration of glucose as a mean to improve glucose tolerance—was suspected even …
administration of glucose as a mean to improve glucose tolerance—was suspected even …
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
JJ Holst - Nature Metabolism, 2024 - nature.com
The introduction of the highly potent incretin receptor agonists semaglutide and tirzepatide
has marked a new era in the treatment of type 2 diabetes and obesity. With normalisation of …
has marked a new era in the treatment of type 2 diabetes and obesity. With normalisation of …
The incretin system and its role in type 2 diabetes mellitus
JJ Holst, T Vilsbøll, CF Deacon - Molecular and cellular endocrinology, 2009 - Elsevier
The incretin hormones are released during meals from gut endocrine cells. They potentiate
glucose-induced insulin secretion and may be responsible for up to 70% of postprandial …
glucose-induced insulin secretion and may be responsible for up to 70% of postprandial …